BRPI0921049A2 - composição sólida para liberação controlada de agentes ativos ionizáveis com solubilidade aquosa pobre a um ph baixo e métodos para uso da mesma - Google Patents

composição sólida para liberação controlada de agentes ativos ionizáveis com solubilidade aquosa pobre a um ph baixo e métodos para uso da mesma

Info

Publication number
BRPI0921049A2
BRPI0921049A2 BRPI0921049A BRPI0921049A BRPI0921049A2 BR PI0921049 A2 BRPI0921049 A2 BR PI0921049A2 BR PI0921049 A BRPI0921049 A BR PI0921049A BR PI0921049 A BRPI0921049 A BR PI0921049A BR PI0921049 A2 BRPI0921049 A2 BR PI0921049A2
Authority
BR
Brazil
Prior art keywords
methods
low
active agents
controlled release
solid composition
Prior art date
Application number
BRPI0921049A
Other languages
English (en)
Inventor
Kane Anil
Ramani Chandir
Lambing Joe
Wang Juan
Chow Kwok
Original Assignee
Portola Pharm Inc
Patheon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41466672&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0921049(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Portola Pharm Inc, Patheon Inc filed Critical Portola Pharm Inc
Publication of BRPI0921049A2 publication Critical patent/BRPI0921049A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
BRPI0921049A 2008-11-14 2009-11-13 composição sólida para liberação controlada de agentes ativos ionizáveis com solubilidade aquosa pobre a um ph baixo e métodos para uso da mesma BRPI0921049A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11500808P 2008-11-14 2008-11-14
US11494108P 2008-11-14 2008-11-14
PCT/US2009/064455 WO2010057036A2 (en) 2008-11-14 2009-11-13 Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI0921049A2 true BRPI0921049A2 (pt) 2017-03-28

Family

ID=41466672

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921049A BRPI0921049A2 (pt) 2008-11-14 2009-11-13 composição sólida para liberação controlada de agentes ativos ionizáveis com solubilidade aquosa pobre a um ph baixo e métodos para uso da mesma

Country Status (13)

Country Link
US (2) US20100151019A1 (pt)
EP (1) EP2376065A2 (pt)
JP (1) JP2012508773A (pt)
KR (1) KR20110097829A (pt)
CN (1) CN102271663A (pt)
AR (1) AR074347A1 (pt)
AU (1) AU2009313867A1 (pt)
BR (1) BRPI0921049A2 (pt)
CA (1) CA2743639A1 (pt)
CL (1) CL2009002073A1 (pt)
RU (1) RU2011123377A (pt)
TW (1) TW201022253A (pt)
WO (1) WO2010057036A2 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
KR101616246B1 (ko) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
MX2010012039A (es) 2008-05-09 2010-11-30 Gruenenthal Gmbh Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio.
RU2015138422A (ru) 2009-07-22 2018-12-25 Грюненталь Гмбх Стабильная при окислении, прочная на излом лекарственная форма
MX2012000317A (es) 2009-07-22 2012-02-08 Gruenenthal Gmbh Forma de dosificacion de liberacion controlada extruida por fusion en caliente.
EP2523657A1 (en) * 2010-01-12 2012-11-21 Portola Pharmaceuticals, Inc. Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011095314A2 (en) 2010-02-03 2011-08-11 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of an extruder
CA2808219C (en) * 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
ES2487244T3 (es) 2010-09-02 2014-08-20 Grünenthal GmbH Forma de dosificación resistente a la manipulación que comprende un polímero aniónico
EP2646434B1 (en) * 2010-12-03 2019-05-15 Portola Pharmaceuticals, Inc. Pharmaceutical compositions, dosage forms and new forms of the compound of formula (i), and methods of use thereof
AU2012292418B2 (en) 2011-07-29 2017-02-16 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
EA201490552A1 (ru) * 2011-09-02 2014-11-28 Новартис Аг Холиновая соль замещенного циклобутендиона, обладающая противовоспалительной способностью
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
CN104394851B (zh) 2012-04-18 2017-12-01 格吕伦塔尔有限公司 抗篡改和抗剂量‑倾泻药物剂型
WO2013167735A1 (en) 2012-05-11 2013-11-14 Grünenthal GmbH Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
HUE025008T2 (en) * 2012-10-12 2016-04-28 Omya Int Ag Gastro-reactive pharmaceutical composition and delivery systems and method for their preparation using functionalized calcium carbonate
AR096438A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
CA2907950A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
BR112016000194A8 (pt) 2013-07-12 2019-12-31 Gruenenthal Gmbh forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
CN105934241B (zh) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 通过低温研磨制备粉末状药物组合物
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
JP2017516789A (ja) 2014-05-26 2017-06-22 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エタノール過量放出に対して防護されている多粒子
AU2015284425B2 (en) * 2014-07-01 2021-04-01 Probi USA, Inc. Bi-layer dual release probiotic tablets
EA034204B1 (ru) * 2014-10-17 2020-01-16 Фидия Фармачеутичи С.П.А. Дермальная терапевтическая система с высокой адгезивной способностью
JP6532153B2 (ja) * 2015-01-30 2019-06-19 ライオン株式会社 内服用錠剤
JP2018503693A (ja) 2015-02-03 2018-02-08 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ポリエチレングリコールグラフトコポリマーを含む改変防止剤形
EP3285745A1 (en) 2015-04-24 2018-02-28 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US10828340B2 (en) * 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en) * 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
WO2018235104A2 (en) * 2017-06-23 2018-12-27 Sun Pharma Advanced Research Company Limited PHARMACEUTICAL FORM SOLID ORAL DISSUASIVE ABUSE
JP7158189B2 (ja) * 2018-07-11 2022-10-21 東洋電装株式会社 スロットルグリップ装置

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
PL1868581T3 (pl) * 2005-04-11 2012-08-31 Abbvie Inc Kompozycje farmaceutyczne słabo rozpuszczalnych leków o polepszonych profilach rozpuszczania
TW200728260A (en) * 2005-11-03 2007-08-01 Portola Pharm Inc Substituted-(quinazolinyl)phenyl thiophenyl-sulfonylureas, methods for making and intermediates thereof
EP2146705B1 (en) * 2007-05-02 2014-03-05 Portola Pharmaceuticals, Inc. Combination therapy with a compound acting as a platelet adp receptor inhibitor

Also Published As

Publication number Publication date
RU2011123377A (ru) 2012-12-20
KR20110097829A (ko) 2011-08-31
WO2010057036A2 (en) 2010-05-20
CL2009002073A1 (es) 2010-12-24
CA2743639A1 (en) 2010-05-20
AR074347A1 (es) 2011-01-12
AU2009313867A1 (en) 2011-06-30
EP2376065A2 (en) 2011-10-19
TW201022253A (en) 2010-06-16
US20100151019A1 (en) 2010-06-17
US20130172374A1 (en) 2013-07-04
JP2012508773A (ja) 2012-04-12
CN102271663A (zh) 2011-12-07
WO2010057036A3 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
BRPI0921049A2 (pt) composição sólida para liberação controlada de agentes ativos ionizáveis com solubilidade aquosa pobre a um ph baixo e métodos para uso da mesma
BR112014014558A2 (pt) composição farmacêutica, uso de um antagonista de crth2 e de um inibidor de bomba de prótons, e, kit para o tratamento de esofagite eosinofílica
BRPI0912252A2 (pt) dispositivos oftálmicos para liberação controlada de agentes ativos.
BRPI0720993A2 (pt) métodos de uso para análogos de ciclopamina
BRPI0919465A2 (pt) dispositivo implantável para a liberação de risperidona e métodos de uso do mesmo
BRPI0918359A2 (pt) composto, composição agroquímica, uso da composição agroquímica e método para preparação do composto
BRPI0818193A2 (pt) composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto
BRPI1011876A2 (pt) "composição farmacêutica estável e métodos de uso da mesma"
BRPI0910335A2 (pt) composição herbicida, uso da mesma, método para controlar vegetação indesejável, e, formulação herbicida
BRPI0918513A2 (pt) formas cristalinas de um derivado de 2-tiazolil-4-quinolinil-óxi, seu sal de sódio, suas composições farmacêuticas e seu uso
BRPI0913109A2 (pt) solução aquosa oftálmica, uso de análogos de pgf2a, e, método para aumentar a solubilidade em água e melhorar a estabilidade de análogos de pgf2a em uma solução aquosa oftálmica
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0906576A2 (pt) Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
BRPI0821732A2 (pt) Formulações de liberação controlada , forma de dosagem sólida, e, uso da formulação de liberação controlada
BRPI0910337A2 (pt) composição herbicida, uso da mesma, método para controlar vegetação indesejável e, formulação herbicida
BRPI0818906A2 (pt) Formulação sólida de liberação rápida, preparação e uso da mesma
BRPI0813749A2 (pt) Uso de homo- copolímeros p, composição de composto ativo, preparação de composto ativo aquosa, uso de uma composição de composto ativo, processo para a preparação de uma dispersão aquosa de compostos ativos orgânicos fracamente solúveis em água, e, dispersão aquosa de compostos ativos orgânicos fracamente solúveis em água
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
BRPI0914069A2 (pt) composição de vacina para uso contra o influenza
BR112012003842A2 (pt) composição farmacêutica, método de formulação e uso da mesma
BRPI0914863A2 (pt) formulação tópica estável, e, uso da mesma
BRPI0809522A2 (pt) Composição farmacêutica sólida, métodos para estabilizar um composto, e para melhorar dissolução de um composto, e, uso de um agente de controle de ph.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]